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Introduction: The aim of the present study was to critically review the incidence of venous thrombo-
embolism and postoperative hemorrhage in patients undergoing total thyroidectomy without preoper-
ative prophylaxis.
Methods: A prospective electronic database of all patients undergoing total thyroidectomy over a six
eyear period within August 2013 in our medical unit was analyzed. The incidence of postoperative
bleeding and Venous thromboembolism (VTE) was reviewed by subgrouping all patients according to a
risk factor score (RFS) for VTE as outlined in the American College of Surgeons National Surgical Quality
Improvement Program (ACS NSQIP) Best Practice Guidelines.
Results: An overall 1018 consecutive patients [244 men (24%, mean age 46 ± 13 years), 778 women (76%,
mean age 44 ± 17 years)] underwent total thyroidectomy. Postoperative bleeding occurred in 8/1018
patients (0.8%). One out of 1018 (0.1%) patients also subcategorized according to the RFS had VTE. The
incidence of VTE complication in the entire population was lower than the risk of postoperative bleeding
(P < .0001).
Conclusion: The risk of developing VTE in patients who undergo total thyroidectomy for benign and
malignant diseases without preoperative prophylaxis is roughly 8-fold less than developing a potentially
life threatening complication as postoperative bleeding. Until large well conducted prospective studies
on the impact of preoperative prophylaxis on postoperative VTE and bleeding will clarify the issue, it is
conceivable to propose the use of stockings and/or anticoagulants according to the individual patient risk
factors.
© 2014 Published by Elsevier Ltd on behalf of Surgical Associates Ltd.1. Introduction
Total thyroidectomy (TT) is a well recognized option to address
benign and malignant thyroid diseases [1,2]. This surgical proce-
dure is associated with different complications that may have an
impact on perioperative surgical outcome [3,4]. During the last
year the development of new technological advancement resulted
in different surgical strategies for the treatment of patients affected
by thyroid pathologies. Surgeons have changed their practice from
a constant towards a tailored approach [5,6] and also improved the
management of perioperative complications such as nerve damageongelli).
f of Surgical Associates Ltd.or bleeding [7e9]. A life-threatening bleeding complication is the
main postoperative concern of most surgeons after thyroidectomy
[10,11]. On the other hand, the American College of Chest Physicians
(ACCP) guidelines recommend deep venous thrombosis (DVT)
prophylaxis in all patients who undergo major surgical procedures
such as thyroidectomy, regardless of anesthesia type [12]. A sys-
tematic review and metanalysis published in 2008 by Lloyd et al.
provided evidence that anticoagulants conferred an absolute risk
reduction in DVT formation, but a signiﬁcantly greater risk of major
bleeding compared to placebo [13].
The aim of the present study was to critically review the inci-
dence of venous thromboembolism and postoperative hemorrhage
in patients undergoing total thyroidectomy without preoperative
prophylaxis.
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2.1. Study design and patient selection
A prospective electronic database of all patients undergoing
total thyroidectomy over a six eyear period within August 2013 in
our medical unit was analyzed. All had no history of prior thyroid or
neck surgery. Patients requiring unilateral lobectomy or subtotal or
completion thyroidectomy were excluded. All patients had normal
renal function at the time of surgery and none had signs or
symptoms indicating metabolic bone disease. No patient was on
medications, such as oral calcium/vitamin D supplementation, anti-
resorptive agents, hormone replacement therapy for post-
menopausal women, anabolic agents, thiazide type diuretics, or
antiepileptic agents. Patients undergoing minimally invasive or
video-assisted procedures were excluded from the study.2.2. Surgical technique
The TT procedure consists of a 3- to 5-cm skin incision 1e1.5 cm
above the sternal notch. After division of the platysma, the cervical
linea alba is opened without division of the strap muscles. The
thyroid lobe is dissected progressively from the strapmuscles. After
identiﬁcation of the recurrent laryngeal nerve and parathyroid
glands, the vascular pedicles of the thyroid lobe are ligated with the
Harmonic Ace/Focus scalpel (Ethicon Endo-Surgery Inc., Cincinnati,
OH, USA), and the thyroid lobe is removed [8,9]. After a check for
hemostasis, a drain is placed in the thyroid bed. The cervical linea
alba and platysma are sutured with absorbable sutures, and the
skin is closed by an intracutaneous running suture. Patients were
asked to take oral calcium 2 g/d taken twice (1 g every 12 h) and
vitamin D 1 g/d taken twice (0.5 g every 12 h) from the night of
operation to post-operative day 14. Intravenous calcium gluconate
was administered if signiﬁcant symptomatic hypocalcaemia per-
sisted after surgery despite oral supplementation. The medical and
nursing notes were carefully examined for documentation of
symptoms of hypocalcaemia. Postoperative hypocalcaemia was
deﬁned as either symptomatic or laboratory. Hypocalcaemia
symptoms and signs, from perioral tingling and numbness to car-
popedal spasms and tetany, were registered in detail. Laboratory
hypocalcaemia was deﬁned as serum total calcium concentrations
of <8.0 mg/dL, even if recorded only in a single measurement. The
time of administration of calcium, vitamin D analogues and intra-
venous ﬂuids in relation to serum calcium and hypocalcaemia
symptoms was also noted. Serum calcium, albumin, creatinine, and
alkaline phosphatase were measured using automated assays. The
reference ranges for serum calcium in our laboratory were
8.5e10.5 mg/dL. Vitamin K antagonists or antiplatelet drugs were
discontinued at least 10 days before operation.Table 1
Preoperative diagnosis.
Disease Total N ¼ 1018
Multinodular goiter 865 (85%)
Carcinoma 112 (11%)
Basedow 41 (4%)2.3. Parameters analyzed
Postoperative bleeding was deﬁned as bleeding after wound
closure that required re-intervention on an Operating room (OR)
basis or on a non-OR basis because of: rapid accumulation of blood,
with more than 150 ml in the suction bottle; visible swelling of the
neck; or symptoms of airway compression. Venous thromboem-
bolism (VTE) was deﬁned as either the occurrence of a pulmonary
embolism (PE) or a deep venous thrombosis (DVT) within 3 months
after total thyroidectomy. Patients were categorized with respect to
the risk of VTE according to a risk factor score (RFS) as outlined in
the American College of Surgeons National Surgical Quality
Improvement Program (ACS NSQIP) Best Practice Guidelines
[14e18].2.4. Statistics
Data were analyzed using SPSS 17.0 for Windows (SPSS Inc,
Chicago, IL). Results were expressed as mean ± SD. Differences in
categorical data were analyzed using the chi square test. Results
were considered statistically signiﬁcant P value was less than 0.05.3. Results
An overall 1018 consecutive patients [244 men (24%, mean age
46 ± 13 years), 778 women (76%, mean age 44 ± 17 years)] un-
derwent total thyroidectomy. The preoperative mean BMI was 26.5
(17e46). Pathologic indications for surgery are listed in Table 1.
Operative time prolonged over 1 h in 285 patients. Patients course
was characterized by several complications. Four patients devel-
oped 4 vocal cord paralysis. Permanent hypocalcaemia developed
only in 11 patients (1%), whereas transient hypocalcaemia was
recorded in 19% of patients (n ¼ 193). Ninety-eight out of 1018
patients developed experienced temporary laryngeal nerve injury
after surgery, with longer lasting voice problems recorded in 48.
Postoperative bleeding occurred in 8/1018 patients (0.8%). One out
of 1018 (0.1%) patients also subcategorized according to risk factors
for venous thromboembolism experienced DVT (Table 2). The
incidence of VTE complication in the entire population was lower
than the risk of postoperative bleeding (P < .0001) (Fig. 1).4. Discussion
The major ﬁnding from this study was that patients who un-
derwent total thyroidectomywithout preoperative prophylaxis had
a very low incidence of postoperative VTE (1/1018). We also
demonstrated that this cohort of patients had a signiﬁcantly greater
risk of developing bleeding complications as evidenced by the
number of cases that required surgical reoperation (8/1018). Post-
operative hemorrhage in the neck is likely to occur as an acute
emergency that can put patients at major risk of airway compro-
mise and death whether not quickly recognized and appropriately
managed. It is true one-day surgery can expose patients to a pre-
dictable consistent risk of bleeding due to lack of postoperative
surveillance carried out by trained health care personnel. In light of
this, patients may not beneﬁt from, but harmed by pharmacologic
VTE prophylaxis. Indeed, VTE is viewed as a serious health care
issue leading to longer hospital stays, increased mortality, and
higher medical costs. Postoperative VTE is a leading cause of
operation-related mortality and as suggested by the latest ACCP
guidelines, pharmacoprophylaxis is recommended in all patients
who undergo major surgical procedures as total thyroidectomy
[19]. In the present study, none of the 1018 patients underwent
preoperative VTE prophylaxis and only 0.1 percent of the entire
cohort developed postoperative deep venous thrombosis without
pulmonary embolism. Previous studies have reported the impact
several risk factors may have on the rate of postoperative VTE after
general and specialist surgery. Moreover, a number of studies have
analyzed the association between cancer and a greater risk of
postoperative VTE after surgery [20e29]. In recent studies, Reinke
and coworkers have recommended tailoring VTE prophylaxis to the
Table 2
Categorical risk factor scores for postoperative VTE after total thyroidectomy
without preoperative prophylaxis.
Total risk
factor score
Risk level category
per ACS NSQIP guidelines
Predicted
incidence
of VTE (%)
Postoperative
incidence
by RFS (%)
0e1 Low risk <10 0.0
2 Moderate risk 10e20 0.0
3e4 High risk 20e40 0.0
5 Highest risk 40e80 0.01
Fig. 1. Incidence of Postoperative Bleeding and Deep Vein Thromboembolism after
total thyroidectomy.
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cedures. Speciﬁcally, they found the absolute incidence of VTE
ranged from nil to 11.9 per 1000 cases, with malignancies of the
thyroid and parathyroid glands having the smallest (1 and 0 cases
respectively). However, authors were not able to demonstrate
thyroid cancer was independently associated with VTE in patients
undergoing thyroidectomy [17,30]. In this study the only patient
developing postoperative venous thrombosis had a multinodular
goiter but the highest RFS as outlined in the ACS NSQIP venous
thromboembolism guidelines for prophylaxis. The present study
had several limitations. It is an observational study not comparing
the incidence of postoperative VTE and bleeding in patients un-
dergoing or not preoperative VTE prophylaxis. Another drawback is
that patients included in this study had 3 distinct surgical diagnosis
that each may carry different morbidity rates. Furthermore, based
on the very low rate of patients with VTE, a lack of a proper power
calculation could not allowanymeaningful conclusions with regard
to predictors of outcome.
In conclusions, we provide evidence that the risk of developing
VTE in patients who undergo total thyroidectomy for benign and
malignant diseases without preoperative prophylaxis is roughly 8-
fold less than developing a potentially life threatening complication
as postoperative bleeding. Until large well conducted prospective
studies on the impact of VTE prophylaxis on postoperative VTE and
bleeding will clarify the issue, it is conceivable to propose VTE
prophylaxis (stockings and/or anticoagulants) according to the in-
dividual patient risk factors.Ethical approval
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